Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a...
Plenary Oral Presentation at SNO will provide latest clinical trial results from the previously enrolled INB-200 studies of autologous gamma-delta T cells for newly diagnosed glioblastoma (GBM...
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0042 | 1.2962962963 | 0.324 | 0.3618 | 0.3036 | 337378 | 0.32551542 | CS |
| 4 | -0.0018 | -0.545454545455 | 0.33 | 0.41 | 0.2621 | 815573 | 0.32022288 | CS |
| 12 | -0.204 | -38.3314543405 | 0.5322 | 0.5566 | 0.217 | 1169294 | 0.38730887 | CS |
| 26 | -0.6918 | -67.8235294118 | 1.02 | 1.74 | 0.217 | 737145 | 0.57015933 | CS |
| 52 | -0.4297 | -56.6961340546 | 0.7579 | 2.48 | 0.217 | 613622 | 0.89385479 | CS |
| 156 | -6.6118 | -95.2708933718 | 6.94 | 7.25 | 0.217 | 668421 | 2.11255077 | CS |
| 260 | -9.6718 | -96.718 | 10 | 10.319 | 0.217 | 609095 | 2.16413186 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
